Atala Financial Inc Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Atala Financial Inc acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 132 shares of the medical research company’s stock, valued at approximately $34,000.

A number of other institutional investors have also recently bought and sold shares of the business. Semus Wealth Partners LLC boosted its position in Amgen by 2.3% during the 3rd quarter. Semus Wealth Partners LLC now owns 1,531 shares of the medical research company’s stock worth $493,000 after acquiring an additional 35 shares during the period. Connable Office Inc. boosted its position in Amgen by 0.5% during the 3rd quarter. Connable Office Inc. now owns 6,972 shares of the medical research company’s stock worth $2,246,000 after acquiring an additional 37 shares during the period. Blossom Wealth Management boosted its position in Amgen by 3.5% during the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock worth $284,000 after acquiring an additional 37 shares during the period. Zullo Investment Group Inc. raised its stake in shares of Amgen by 2.8% during the 4th quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after purchasing an additional 37 shares in the last quarter. Finally, Brooklyn Investment Group raised its stake in shares of Amgen by 1.1% during the 3rd quarter. Brooklyn Investment Group now owns 3,377 shares of the medical research company’s stock worth $1,088,000 after purchasing an additional 38 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $313.71 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business’s 50 day moving average is $291.82 and its two-hundred day moving average is $299.52. The company has a market cap of $168.53 billion, a P/E ratio of 41.55, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is presently 126.09%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on AMGN shares. Piper Sandler raised their price target on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Wolfe Research started coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Finally, Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $314.04.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. This trade represents a 12.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.